{"id":306236,"date":"2010-02-11T06:40:26","date_gmt":"2010-02-11T11:40:26","guid":{"rendered":"http:\/\/www.xconomy.com\/?p=62815"},"modified":"2010-02-11T06:40:26","modified_gmt":"2010-02-11T11:40:26","slug":"halozyme-pursues-anti-cellulite-drug-optimer%e2%80%99s-antibiotic-kills-c-difficile-germs-tragara-pharmaceuticals-raises-funds-more-san-diego-life-sciences-news","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/306236","title":{"rendered":"Halozyme Pursues Anti-Cellulite Drug, Optimer\u2019s Antibiotic Kills C. Difficile Germs, Tragara Pharmaceuticals Raises Funds & More San Diego Life Sciences News"},"content":{"rendered":"\n
Roundup<\/a>, Life Sciences funding<\/a>, drug discovery<\/a><\/div>\n

\t\tDenise Gellene wrote:<\/strong><\/p>\n

There was a steady flow of drug development and funding news from San Diego’s life sciences industry over the past week. Here are the highlights.<\/p>\n

—Halozyme Therapeutics<\/strong> (NASDAQ: HALO<\/a>) CFO Kurt Gustafson talked with me about the experimental anti-cellulite drug <\/a> that company is testing in preclinical studies.<\/p>\n

—Connect<\/strong>, a non-profit that supports local technology and entrepreneurship, opened a lobbying office in Washington D.C. <\/a>to represent San Diego’s innovation community.<\/p>\n

—PatientSafe Solutions<\/strong>, formerly IntelliDOT, a company working on technology to prevent errors in hospitals<\/a>, raised $30 million in a restructuring round of funding.<\/p>\n

—An experimental antibiotic from Optimer Pharmaceuticals<\/strong> (NASDAQ: OPTR<\/a>) was <\/a>equivalent in a clinical trial to mainstay drug vancomycin against C.difficile<\/em> bacterial infections<\/a>. The company expects to fil e a new drug application with the FDA later this year.<\/p>\n

—Sequenom<\/strong> (NASDAQ: SQMN<\/a>)) obtained rights to develop and commercialize a genetic test for late-stage, age-related macular degeneration<\/a>, the leading cause of blindness in the elderly.<\/p>\n

—NexMed<\/strong> (NASDAQ: NEXM<\/a>) raised $2.3 million in promissory notes <\/a>from two investors for general corporate purposes and to advance its transdermal drug delivery technology.<\/p>\n

—Tragara Pharmaceuticals<\/strong>, a company focused on anti-tumor drugs, has raised $5 million<\/a> of a targeted $10 million venture round.<\/p>\n

—Isis Pharmaceuticals<\/strong> of Carlsbad, CA (NASDAQ: ISIS<\/a>) and Cambridge, MA-based partner Genzyme (NASDAQ: GENZ<\/a>) said an experimental drug lowered cholesterol in patients with familial hypercholesterolemia<\/a>, an inherited disorder that affects 1 in 500 people. Patients in the late-stage study had higher liver enzymes but no liver dysfunction, the companies said.<\/p>\n

Comments<\/a> | Reprints<\/a> | Share:  
\n\"Retweet\"\/<\/a>
\n \"Facebook\"\/<\/a>
\n \"Email\"\/<\/a>
\n \"Share\"\/<\/a>\n<\/div>\n

\t \t\t

\n

\n\"\"<\/a>
\n\"\"<\/p>\n

<\/img><\/a>
\n<\/img><\/a><\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Roundup, Life Sciences funding, drug discovery Denise Gellene wrote: There was a steady flow of drug development and funding news from San Diego’s life sciences industry over the past week. Here are the highlights. —Halozyme Therapeutics (NASDAQ: HALO) CFO Kurt Gustafson talked with me about the experimental anti-cellulite drug that company is testing in preclinical […]<\/p>\n","protected":false},"author":2918,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-306236","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/306236","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/2918"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=306236"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/306236\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=306236"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=306236"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=306236"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}